4 research outputs found
The molecular basis of beta-thalassemia intermedia in southern China: genotypic heterogeneity and phenotypic diversity
<p>Abstract</p> <p>Background</p> <p>The clinical syndrome of thalassemia intermedia (TI) results from the β-globin genotypes in combination with factors to produce fetal haemoglobin (HbF) and/or co-inheritance of α-thalassemia. However, very little is currently known of the molecular basis of Chinese TI patients.</p> <p>Methods</p> <p>We systematically analyzed and characterized β-globin genotypes, α-thalassemia determinants, and known primary genetic modifiers linked to the production of HbF and the aggravation of α/β imbalance in 117 Chinese TI patients. Genotype-phenotype correlations were analyzed based on retrospective clinical observations.</p> <p>Results</p> <p>A total of 117 TI patients were divided into two major groups, namely heterozygous β-thalassemia (n = 20) in which 14 were characterized as having a mild TI with the Hb levels of 68-95 g/L except for five co-inherited ααα<sup>anti-3.7 </sup>triplication and one carried a dominant mutation; and β-thalassemia homozygotes or compound heterozygotes for β-thalassemia and other β-globin defects in which the β<sup>+</sup>-thalassemia mutation was the most common (49/97), hemoglobin E (HbE) variants was second (27/97), and deletional hereditary persistence of fetal hemoglobin (HPFH) or δβ-thalassemia was third (11/97). Two novel mutations, Term CD+32(A→C) and Cap+39(C→T), have been detected.</p> <p>Conclusions</p> <p>Chinese TI patients showed considerable heterogeneity, both phenotypically and genotypically. The clinical outcomes of our TI patients were mostly explained by the genotypes linked to the β- and α-globin gene cluster. However, for a group of 14 patients (13 β<sup>0</sup>/β<sup>N </sup>and 1 β<sup>+</sup>/β<sup>N</sup>) with known heterozygous mutations of β-thalassemia and three with homozygous β-thalassemia (β<sup>0</sup>/β<sup>0</sup>), the existence of other causative genetic determinants is remaining to be molecularly defined.</p
Genetic modifiers of Hb E/β<sup>0 </sup>thalassemia identified by a two-stage genome-wide association study
<p>Abstract</p> <p>Background</p> <p>Patients with Hb E/β<sup>0 </sup>thalassemia display remarkable variability in disease severity. To identify genetic modifiers influencing disease severity, we conducted a two-stage genome scan in groups of 207 mild and 305 severe unrelated patients from Thailand with Hb E/β<sup>0 </sup>thalassemia and normal α-globin genes.</p> <p>Methods</p> <p>First, we estimated and compared the allele frequencies of approximately 110,000 gene-based single nucleotide polymorphisms (SNPs) in pooled DNAs from different severity groups. The 756 SNPs that showed reproducible allelic differences at <it>P </it>< 0.02 by pooling were selected for individual genotyping.</p> <p>Results</p> <p>After adjustment for age, gender and geographic region, logistic regression models showed 50 SNPs significantly associated with disease severity (<it>P </it>< 0.05) after Bonferroni adjustment for multiple testing. Forty-one SNPs in a large LD block within the β-globin gene cluster had major alleles associated with severe disease. The most significant was bthal_bg200 (odds ratio (OR) = 5.56, <it>P </it>= 2.6 × 10<sup>-13</sup>). Seven SNPs in two distinct LD blocks within a region centromeric to the β-globin gene cluster that contains many olfactory receptor genes were also associated with disease severity; rs3886223 had the strongest association (OR = 3.03, <it>P </it>= 3.7 × 10<sup>-11</sup>). Several previously unreported SNPs were also significantly associated with disease severity.</p> <p>Conclusions</p> <p>These results suggest that there may be an additional regulatory region centromeric to the β-globin gene cluster that affects disease severity by modulating fetal hemoglobin expression.</p